Bucladesine - Daiichi Pharmaceutical

Drug Profile

Bucladesine - Daiichi Pharmaceutical

Alternative Names: Actosin; DT 5621

Latest Information Update: 20 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Pharmaceutical
  • Class Cardiotonics; Nucleotides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Skin ulcer

Most Recent Events

  • 20 Feb 2001 A study has been added to the Skin Disorders therapeutic trials and adverse events sections
  • 28 Dec 2000 Discontinued-III for Skin ulcer in USA (Topical)
  • 29 Jan 1998 Phase-III clinical trials for Skin ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top